BioSpace News Archive

The JAMP Pharma Group is pleased to announce the launch of PrJAMP Dapagliflozin, a generic alternative to the reference product Forxiga® d’Astrazeneca Canada Inc.

Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities announced the expansion of the Advanced Cell Diagnostics -branded RNAscope™ in situ hybridization portfolio with the release of a RNAscope multiomic workflow for the Standard BioTools Hyperion™ Imaging System.

YS Biopharma Co., Ltd. today announced its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from the Drug Regulatory Authority of Pakistan (“DRAP”).

Labcorp, a leading global life sciences company, announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations.

Kimera® Labs Inc. is pleased to announce the FDA IND (Investigational New Drug) approval of its exosomes in a Phase I/IIa clinical trial.

Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a comparator, IV brexanolone.

Viking Therapeutics, Inc. today announced positive top-line results from its Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

Alkermes plc announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® and ARISTADA® —at four scientific conferences this spring.

Intergalactic Therapeutics announced today that it will host a virtual investor event with scientific experts in the fields of ophthalmology, bioengineering, and gene therapy on Tuesday, May 23, 2023 at 10:00 a.m. ET.

Terray Therapeutics today announced the appointment of Sudha Parasuraman, MD, as an Independent Director.